Nucleus Network Pty Ltd

Nucleus Network Pty Ltd

Current logo in use since 2020
Trading name	Nucleus Network
Formerly	Centre for Clinical Studies (Rebranded), Prism Clinical Research (Acquired in 20218) Q-Pharm (Acquired in 2019)
Type	Privately held company
ISIN	🆔
Industry	Medical Research
Predecessor	Centre for Clinical Studies
Founded 📆	2004
Founder 👔
Headquarters 🏙️	, Melbourne, Australia
Area served 🗺️
Owner	Majority owned by Blackstone Group since 2022
Members
Number of employees	400+
🌐 Website	nucleusnetwork.com
📇 Address
📞 telephone

Nucleus Network is a Clinical Trial administrator with clinics in Melbourne and Brisbane in Australia, and Minneapolis in the USA, as well as satellite facilities in Geelong and Gold Coast.

Locations

Nucleus Network operates out of three major clinics, each within established medical precincts.

Melbourne

The Melbourne clinic is housed in the Burnet building within The Alfred hospital precinct. This location is the original clinic established in 2004, and has remained largely the same since being outfitted for a clinical trial hosting site.

While the clinic's main access is from street-level elevators, there are additional emergency access elevators that are linked with The Alfred hospital, allowing the rapid movement of people in case of emergency.

Brisbane

The Brisbane clinic is situated in the Clive Berghofer Cancer Research Centre (CBRC Building) within the Royal Brisbane Hospital precinct in Herston, Queensland. The clinic spans two levels with recent renovations to the laboratory section and upgrades to the reception area.

This site specialises in vaccination and biosimilar studies, and was previously the site of Q-Pharm before it was acquired by Nucleus Network in 2019.

Minneapolis

Located within the medical alley precinct in the University Enterprise Laboratories (UEL) Building, the Minneapolis clinic specialises in clinical trials that study the effects on patients with renal or hepatic impairment.

History

Founding

In 2001, the Victorian State Government identified the need to invest in extending the capabilities of medical research within the state to improve health outcomes. Initially a department within the Baker IDI Heart and Diabetes Institute, then-Director Professor Gary Jennings, AO identified the need to increase the capabilities of the facility to host clinical trials that would measure up to stringent international standards and be able to compete with clinical trial administration entities throughout the world.

Purchase by Crescent Capital

In early 2018, The Baker Heart and Diabetes Institute announced the sale of Nucleus Network to Australian private equity firm, Crescent Capital Partners. With the institute’s focus on research and the expanding opportunities of clinical trials administration, the funds from the sale allowed the Baker Institute to invest more funds in the specialised research that had long been their primary purpose.

Purchase by Blackstone Group

During 2021, Crescent Capital Partners began the search for a buyer for Nucleus Network, with a reported price expected to exceed $600 million. While the initial purchase price in 2018 was not made public,

References

This article "Nucleus Network" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Nucleus Network. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

---